HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

L-902688

a prostanoid receptor EP4 agonist

Also Known As:

(5R)-5-((1E,3R)-4,4-difluoro-3-hydroxy-4-phenyl-1-buten-1-yl)-1-(6-(2H-tetrazol-5-yl)hexyl)-2-pyrrolidinone; L-902,688

Networked: 7 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Tetrazoles: 14
      - L-902688: 7
  - Pyrrolidines: 115
    - Pyrrolidinones: 162
      - L-902688: 7

Experts

1.	Avsec, Damjan: 2 articles (01/2022 - 01/2021)
2.	Markovič, Tijana: 2 articles (01/2022 - 01/2021)
3.	Mlinarič-Raščan, Irena: 2 articles (01/2022 - 01/2021)
4.	Nabergoj, Sanja: 2 articles (01/2022 - 01/2021)
5.	Podgornik, Helena: 2 articles (01/2022 - 01/2021)
6.	Chen, I-Chen: 2 articles (03/2018 - 01/2018)
7.	Huang, Chung-Chi: 2 articles (03/2018 - 01/2018)
8.	Lai, Ying-Ju: 2 articles (03/2018 - 01/2018)
9.	Li, Hsin-Hsien: 2 articles (03/2018 - 01/2018)
10.	Al-Kandery, Al-Shaimaa A: 1 article (11/2021)

Related Diseases

1.	Ischemic Stroke 01/01/2018 - "Rats underwent transient ischemic stroke for 90 min. Animals received an intravenous injection of either the vehicle or L-902,688, a highly specific EP4 agonist, at the onset of reperfusion. " 01/01/2018 - "Protective Effects of L-902,688, a Prostanoid EP4 Receptor Agonist, against Acute Blood-Brain Barrier Damage in Experimental Ischemic Stroke." 01/01/2018 - "Our data show for the first time that pharmacological activation of EP4 with L-902,688 is neuroprotective in ischemic stroke by reducing MMP-3/-9 and BBB damage."
2.	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/01/2021 - "EP4 receptor agonist L-902688 augments cytotoxic activities of ibrutinib, idelalisib, and venetoclax against chronic lymphocytic leukemia cells." 01/29/2022 - "Herein, we report that EP4 receptor agonists PgE1-OH and L-902688 have exhibited enhanced cytotoxicity when applied together with anti-CD20 MAbs rituximab, ofatumumab and obinutuzumab in vitro in Burkitt lymphoma cells Ramos, as well as in p53-deficient chronic lymphocytic leukemia (CLL) cells MEC-1. "
3.	Pulmonary Arterial Hypertension 03/03/2018 - "EP4 Agonist L-902,688 Suppresses EndMT and Attenuates Right Ventricular Cardiac Fibrosis in Experimental Pulmonary Arterial Hypertension." 01/01/2018 - "Prostanoid EP4 agonist L-902,688 activates PPARγ and attenuates pulmonary arterial hypertension."
4.	Vascular Remodeling 01/01/2018 - "L-902,688 attenuated pulmonary arterial remodeling in hypoxic PAH mice and MCT-induced PAH rats; therefore, we conclude that the selective EP4 agonist L-902,688 reverses vascular remodeling by activating PPARγ. " 01/01/2018 - "Isolated PASMCs from MCT-induced PAH rats (MCT-PASMCs) were treated with L-902,688, a selective EP4 agonist, to investigate the anti-vascular remodeling effect. "
5.	B-Cell Lymphoma (Lymphoma, B Cell) 01/01/2021 - "As prostaglandin E (EP)4 receptor agonists have been shown to successfully inhibit the NF-κB pathway in B-cell lymphoma cells, we investigated the potential of the highly specific EP4 receptor agonist L-902688 for the potential treatment of patients with CLL. "

Related Drugs and Biologics

1.	Prostaglandins
2.	Occludin
3.	Tight Junction Proteins
4.	Matrix Metalloproteinases (MMPs)
5.	Rituximab (Mabthera)
6.	venetoclax
7.	idelalisib
8.	ibrutinib
9.	obinutuzumab
10.	ofatumumab

Related Therapies and Procedures

1.	Therapeutics
2.	Intravenous Injections